To investigate the curative effects of GLP-2 on short bowel syndrome, we established the type 2 SBS model in SD rats and 100 μg/kg GLP-2 or vehicle were injected subcutaneously once daily for 2 weeks (Figure 1A-B). The gene discussed is GCG; the disease is short bowel syndrome.